-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2202 In Utero mRNA Lipid Nanoparticle Delivery in a Murine Model of Fanconi Anemia

Program: Oral and Poster Abstracts
Session: 801. Gene Therapies: Poster I
Hematology Disease Topics & Pathways:
Gene Therapy, Treatment Considerations, Biological therapies
Saturday, December 7, 2024, 5:30 PM-7:30 PM

Linah Omer, MD1, William Johnston, MD2*, Sarah Adams, BS1*, Omar Banda, PhD1*, Elena Sofia Vivona, MD1*, Stefano Rivella, PhD3,4, Mohamad-Gabriel Alameh, phD5*, William Peranteau, MD6* and Peter Kurre, MD7,8

1Comprehensive Bone Marrow Failure Center, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
2Department of medicine, University of Pennsylvania, Philadelphia
3Penn Institute for RNA Innovation, University of Pennsylvania, Philadelphia, PA
4Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA
5Department of Medicine, University of Pennsylvania, Philadelphia, PA
6The Children's Hospital of Philadelphia, Philadelphia, PA
7Comprehensive Bone Marrow Failure Center, Children's Hospital of Philadelphia, Philadelphia, PA
8Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

Fanconi anemia (FA) is a rare multisystem genetic disorder characterized by defects in DNA repair, cancer predisposition and early failure of the hematopoietic system. Hematopoietic stem cell (HSC) transplant is curative, but eligibility is limited by donor availability. Alternatively, early phase clinical trials of lentiviral HSC gene transfer show great promise but remain constrained by a depleted HSC pool in older patients, ineffective mobilization, and HSC sensitivity to ex vivo manipulation. Recent studies revealed the fetal onset of HSC depletion in FA before the later manifestation of peripheral cytopenia, suggesting that prenatal gene therapy offers a minimally invasive, potentially preventive approach during fetal immune tolerance. Building on the successful use of lipid nanoparticles (LNP) for mRNA vaccines and for treatment of monogenic metabolic disorders; we hypothesize that LNP delivery of modified Fancc mRNA for protein replacement may rescue fetal HSC pool expansion and delay postnatal HSC attrition in Fancc-/- (KO) mice.


To demonstrate feasibility, we used 5’ Clean Cap, 101 poly-A tail methyl-pseudouridine modified luciferase mRNA packaged into LNPs (diameter 80 ± 5nm; PDI 0.01) and compared the half-life of linear vs. circular constructs. C57BL/6 mouse bone marrow derived hematopoietic stem and progenitor cells (HSPC) treated with circularized luciferase mRNA had detectable luminescence for up to 7 days as compared to 4 days when using linear mRNA. To test FA phenotype rescue, we used polyvinyl-EtOH supplemented ex vivo expansion of Fancc-/- CD150+ CD48- Lin- Sca1+ c-kit+ long term (LT- HSC) as a novel assay to test for HSPC proliferation. We showed that a single dose of circular LNPFancc (LNPCFancc) improved HSPC tolerance to mitomycin (MMC) up to 5 days, compared with 3 days upon treatment with Linear LNPFancc. To further verify functionality on ex vivo expanded LT-HSC, serial treatment with LNPCFancc days 0, -7 and -14 resulted in significantly improved Fancc-/- doubling time, reaching wildtype (WT) equivalence by day 14. This was accompanied by significantly improved progenitor colony formation. For an in vivo assessment of LNPCFancc on prenatal HSC expansion, C57BL/6 Fancc+/− heterozygote pregnancies were used to generate Fancc-/- and Fancc+/+ (WT) littermate fetuses. Baseline analysis of Fancc-/- embryos at gestational age day E15.5 showed higher numbers of KO fetuses, 26% as compared to 14% observed P21 postnatally, suggesting a late gestational lethality. Compared to their wildtype WT littermates, KO fetus’ weights and total fetal liver cell count were 87% and 72% of WT, respectively. In the fetal HSPC compartment, single vitelline vein injections of LNPCFancc to embryos at E14.5 resulted in small improvements in short term (ST-HSC) and LT-HSC without significant effect on myeloid or lymphoid progenitor cell population. However, LNPCFancc treatment improved colony formation of sorted KSL cells (c-Kit+ Sca-1+ Lin-), reaching 81% of WT level (from a 69% lower baseline) and conferred a significant improvement in MMC tolerance by 2-fold over untreated controls.


In conclusion, our data show that protein replacement with LNPCFancc can support FA HSPC function and proliferation. While transient, this method for protein replacement to HSC during rapid fetal liver expansion may rescue expansion of the FA HSC pool and delay the onset of postnatal bone marrow failure. Our study provides further evidence that in utero LNP delivery of mRNA can ameliorate fetal phenotype in FA and sets the stage for gene editing in FA as a curative approach.

Disclosures: Rivella: BVF Partners L.P.: Consultancy; Techspert.io: Consultancy; Slingshot Insight: Consultancy; Protagonist Therapeutics: Consultancy; BMS: Consultancy; BioMarin: Consultancy; Disc Medicine: Membership on an entity's Board of Directors or advisory committees, Research Funding; Vifor: Membership on an entity's Board of Directors or advisory committees; Ionis Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees; venBio Select LLC: Consultancy; LifeSci Capital: Consultancy.

<< Previous Abstract | Next Abstract
*signifies non-member of ASH